{"page":{"totalFilteredElements":14},"studies":[{"active":true,"description":"Adjuvant Dynamic marker - Adjusted Personalized Therapy \ncomparing adjuvant Elacestrant with standard endocrine \ntreatment in genomically and/or clinically high-risk ER+/HER2- \nearly breast cancer","eudractNumber":"2025-522484-15-00","id":12036,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT07242352","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-06-23T11:08:21+02:00","shortTitle":"ADAPTela","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A randomized phase 3, double-blind, placebo-controlled study of elacestrant in patients with estrogen receptor - positive/ human groth factor receptor 2 negative, ESR1-mutaed, advanced breast cancer progressing to endocrine therapy and CDK 4/6 inhibitors","eudractNumber":"2024-512926-27-00","id":12013,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"ESR1 (Estrogen Receptor 1 Gen)","id":"mt_207"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06382948","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":null,"shortTitle":"ADELA","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"<div>Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations</div>","eudractNumber":"2025-521284-12-00","id":11553,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT07195695","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-05-18T15:27:57+02:00","shortTitle":"BI - 1479-0032 - Beamion LUNG 3","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of \nBMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung \nCancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies","eudractNumber":"2024-519814-29","id":10710,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"EGFR","id":"mt_1"},{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF","id":"mt_9"},{"name":"ALK","id":"mt_11"},{"name":"ROS-1 (c-ros oncogene 1, receptor tyrosine kinase)","id":"mt_12"},{"name":"HER2/neu","id":"mt_19"},{"name":"RET (Rezeptor-Tyrosinkinase)","id":"mt_76"},{"name":"NTRK","id":"mt_81"}],"nctNumber":"NCT06855771","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-09-12T13:09:19+02:00","shortTitle":"BMS-CA240-0009","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular patterns of Ribociclib efficacy and resistance in advanced breast cancer patients","eudractNumber":"2022-000637-16","id":8438,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"},{"name":"PgR-","id":"mt_50"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT05452213","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2022-11-23T11:54:11+01:00","shortTitle":"CAPTOR-BC","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"<div>A non-interventional study for Kisqali (Ribociclib) in combination with an aromatase inhibitor in patients with HR+/HER2- stage II and III early breast cancer to evaluate</div><div>real-world effectiveness, safety profile, patient compliance and quality of life (CAROLEEN).</div>","eudractNumber":null,"id":10286,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06830720","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-02-26T12:10:01+01:00","shortTitle":"CAROLEEN","therapeutical":false,"therapyLines":[]},{"active":true,"description":"DESTINY-Biliary\nTract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and\nRilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab\nfor First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract\nCancer","eudractNumber":"2023-508057-19-00","id":10413,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06467357","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-04-14T09:21:26+02:00","shortTitle":"DESTINY-BTC 01 D781PC00001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with with primary high-risk lobular breast cancer - LOBSTER","eudractNumber":"2023-509292-17-00","id":9924,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06607757","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-12-11T11:29:15+01:00","shortTitle":"LOBSTER","therapeutical":true,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"<div>A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive. A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer.</div>","eudractNumber":"2024-519773-19","id":11702,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06901531","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-16T11:09:29+02:00","shortTitle":"Lucerna","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focos on digital side effect management","eudractNumber":"2021-000287-30","id":8045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"}],"nctNumber":"NCT05362760","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2022-12-01T13:42:29+01:00","shortTitle":"Minerva","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}